Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M M Oken

Showing results (61-70 of 148) with videos related to

Pageof 15
Sort By:
Cancer|April 15, 1997
Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479M M Oken, D P Harrington, N Abramson, et al.
The New England Journal of Medicine|November 11, 1982
Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphomaJ J Yunis, M M Oken, M E Kaplan, et al.
The New England Journal of Medicine|April 20, 1989
bcl-2 and other genomic alterations in the prognosis of large-cell lymphomaJ J Yunis, M G Mayer, M A Arnesen, et al.
The American Journal of Medicine|September 1, 1976
IgM pyroglobulinemia with erythrocytosis presenting as hyperviscosity syndrome. I. Clinical features and viscometric studiesS R McCann, H H Zinneman, M M Oken, et al.
Leukemia & Lymphoma|April 8, 1999
Altered T cell repertoire usage in CD4 and CD8 subsets of multiple myeloma patients, a Study of the Eastern Cooperative Oncology Group (E9487)N Kay, T Leong, R A Kyle, et al.
Leukemia & Lymphoma|January 1, 1995
Sequential phenotyping of myeloma patients on chemotherapy: persistence of activated T-cells and natural killer cellsN E Kay, M M Oken, R Kyle, et al.
Blood|December 1, 1991
Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: a technique for sequential quantitation of residual diseaseD Billadeau, M Blackstadt, P Greipp, et al.
Urologic Oncology|January 13, 2011
A phase II trial of melphalan or thioguanine in the treatment of patients with advanced renal cell cancerR S Witte, P Elson, J A Stewart, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 1, 1997
Immunomodulatory function of interferon-gamma in patients with metastatic melanoma: results of a phase II-B trial in subjects with metastatic melanoma, ECOG study E 4987. Eastern Cooperative Oncology GroupJ M Kirkwood, J Bryant, J H Schiller, et al.
Blood|June 1, 1986
Refined chromosome analysis as an independent prognostic indicator in de novo myelodysplastic syndromesJ J Yunis, R E Rydell, M M Oken, et al.
Pageof 15

Showing results (61-70 of 148) with videos related to

Sort By:
Pageof 15
Cancer|April 15, 1997
Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479M M Oken, D P Harrington, N Abramson, et al.
The New England Journal of Medicine|November 11, 1982
Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphomaJ J Yunis, M M Oken, M E Kaplan, et al.
The New England Journal of Medicine|April 20, 1989
bcl-2 and other genomic alterations in the prognosis of large-cell lymphomaJ J Yunis, M G Mayer, M A Arnesen, et al.
The American Journal of Medicine|September 1, 1976
IgM pyroglobulinemia with erythrocytosis presenting as hyperviscosity syndrome. I. Clinical features and viscometric studiesS R McCann, H H Zinneman, M M Oken, et al.
Leukemia & Lymphoma|April 8, 1999
Altered T cell repertoire usage in CD4 and CD8 subsets of multiple myeloma patients, a Study of the Eastern Cooperative Oncology Group (E9487)N Kay, T Leong, R A Kyle, et al.
Leukemia & Lymphoma|January 1, 1995
Sequential phenotyping of myeloma patients on chemotherapy: persistence of activated T-cells and natural killer cellsN E Kay, M M Oken, R Kyle, et al.
Blood|December 1, 1991
Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: a technique for sequential quantitation of residual diseaseD Billadeau, M Blackstadt, P Greipp, et al.
Urologic Oncology|January 13, 2011
A phase II trial of melphalan or thioguanine in the treatment of patients with advanced renal cell cancerR S Witte, P Elson, J A Stewart, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 1, 1997
Immunomodulatory function of interferon-gamma in patients with metastatic melanoma: results of a phase II-B trial in subjects with metastatic melanoma, ECOG study E 4987. Eastern Cooperative Oncology GroupJ M Kirkwood, J Bryant, J H Schiller, et al.
Blood|June 1, 1986
Refined chromosome analysis as an independent prognostic indicator in de novo myelodysplastic syndromesJ J Yunis, R E Rydell, M M Oken, et al.
Pageof 15